Literature DB >> 9043748

Responses in skin microcirculation to vestibular stimulation before and during motion sickness.

O I Kolev1, C Möller, G Nilsson, L Tibbling.   

Abstract

BACKGROUND: Observation of physiological changes during motion sickness is required to quantify the degree of sickness. The review of the literature does not show unifying results. An objective symptom of motion sickness is facial pallor. It reflects changes in skin microcirculation which have not been measured so far.
METHODS: Eleven healthy volunteers susceptible to motion sickness were subjected to eccentric vertical axis rotation. The dynamics and the correspondence of the changes in skin blood flow in two segments, forehead and finger, were measured by laser Doppler flowmeter. RESULTS AND
CONCLUSIONS: The difference in the microcirculatory skin blood flow across the phases of motion sickness is significant for the forehead but not for the fingertip: the established dynamics of the forehead blood flow during motion sickness will be of benefit in quantifying the degree of sickness; there is no correlation between the blood flow changes in both measured areas; the rhythmic blood flow fluctuation increases during motion sickness; there is a difference between the blood flow responses to vestibular stimulation before the appearance of motion sickness and in the course of the sickness. Laser Doppler flowmetry is a reliable method in quantifying the degree of motion sickness.

Entities:  

Mesh:

Year:  1997        PMID: 9043748     DOI: 10.1017/s0317167100021090

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  2 in total

1.  Motion sickness potentiates core cooling during immersion in humans.

Authors:  I B Mekjavic; M J Tipton; M Gennser; O Eiken
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

Review 2.  What is nausea? A historical analysis of changing views.

Authors:  Carey D Balaban; Bill J Yates
Journal:  Auton Neurosci       Date:  2016-07-16       Impact factor: 3.145

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.